Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Sector: Medical
LXRX (NASDAQ: LXRX)
3m
6m
1y
2y
Ranking History
This Week
Last Week
Two Weeks Back
Three Weeks Back
Please login to view our current ranking data
Click here to login
No Information
No Information
No Information
Disclaimer
Headlines
Blog Articles
Premium News
Press Releases
SEC
Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
Nov 23, 2009 08:31 AM |
LXRX
Ridgewater Equity Trend and Financial Analysis of Generex Biotechnology Corp., Allscripts-Misys Healthcare Solutions Inc., Lexicon Pharmaceuticals Inc., ATP Oil & Gas Corp., TeleCommunication Systems Inc. and Charming Shoppes Inc.
Nov 20, 2009 08:11 AM |
ATPG
,
CHRS
,
GNBT
,
LXRX
,
TSYS
Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome
Nov 12, 2009 05:08 PM |
LXRX
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Third Quarter Financial Results
Oct 27, 2009 06:30 AM |
LXRX
Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2009 Financial Results on October 27, 2009
Oct 20, 2009 06:30 AM |
LXRX
Lexicon Announces Completion of Public Offering of Common Stock
Oct 14, 2009 04:45 PM |
LXRX
Lexicon Announces Pricing of Common Stock in Public Offering
Oct 08, 2009 06:48 PM |
LXRX
,
MS
Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
Oct 07, 2009 04:43 PM |
LXRX
,
MS
Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
Sep 15, 2009 06:30 AM |
LXRX
Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Sep 09, 2009 06:30 AM |
LXRX
,
MS
More..
BRIEF: Corporate Layoffs Affect 200 Locally
Jan 24, 2009 07:52 AM |
LXRX
More..
Ridgewater Equity Trend and Financial Analysis of Generex Biotechnology Corp., Allscripts-Misys Healthcare Solutions Inc., Lexicon Pharmaceuticals Inc., ATP Oil & Gas Corp., TeleCommunication Systems Inc. and Charming Shoppes Inc.
Nov 20, 2009 09:58 AM |
ATPG
,
CHRS
,
GNBT
,
LXRX
,
MDRX
,
TSYS
Stock on the Move: SUWN -- September 16, 2009
Sep 16, 2009 09:51 AM |
CTIC
,
LXRX
,
SUWN
,
THC
Lexicon Initiates Phase 2 Clinical Trial of LX2931 in Patients With Rheumatoid Arthritis
Aug 04, 2009 06:30 AM |
LXRX
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results
Jul 28, 2009 06:31 AM |
LXRX
Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
Jul 22, 2009 06:30 AM |
LXRX
Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
Jul 21, 2009 06:30 AM |
LXRX
Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
Jul 07, 2009 06:30 AM |
LXRX
Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
Jun 02, 2009 06:30 AM |
LXRX
Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
May 27, 2009 08:12 AM |
LXRX
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
Apr 28, 2009 06:30 AM |
LXRX
More..
Form 4 LEXICON PHARMACEUTICALS, For: Oct 22 Filed by: BARKER SAM L (10K)
Oct 26, 2009 05:58 PM
Form 4 DEBBANE RAYMOND For: Oct 14 (10K)
Oct 15, 2009 05:42 PM
Form 4 BANSAL AJAY For: Jun 02 (10K)
Jun 02, 2009 07:14 PM
Form 3 BANSAL AJAY For: Jun 02 (10K)
Jun 02, 2009 07:14 PM
More..
Analyst Ratings
More Details
Sentiment Survey
Avg. Short Term
Avg. Long Term
Avg. Grade
More Details
Share Performance
Period
LXRX
Compare to S&P
YTD
7.14 %
-11.33 %
4 Weeks
-3.23 %
-4.27 %
12 Weeks
0.67 %
-5.09 %
More...
Financial Ratios
Earnings Performance
EPS Growth in Last Quarter:
6.67 %
EPS Growth in Last Year:
6.67 %
Sales Growth in Last Quarter:
-28.71 %
Sales Growth in Last Quarter:
-71.63 %
More...
{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
